Ann: Preliminary Final Report, page-14

Another day at the big pharma office at Astra Zeneca and what have we here.

Despite encouraging midstage data for AstraZeneca’s drug for systemic lupus erythematosus (SLE), anifrolumab has missed the target in the first of two ongoing phase 3 trials, putting its future in doubt.

The antibody, which binds to and inhibits the subunit 1 of the type I interferon receptor and is designed to dampen down the activity of inflammatory cytokines, was unable to achieve a significant reduction in disease activity compared to placebo over the one-year TULIP 1 trial.

Ouch folks. But big pharma has the ability to take a kick right where it hurts especially when there are literally multiple billions of dollars at stake. Take a look at the actual simplicity of our acne product only, let alone the atopic dermatitis product or anything else for that matter. I reckon there will be more surprises in this skin game. That chief medical officer recently appointed loves a bagel but i reckon he hates scuba diving as the chances of him finding four skin divers in New Yorks money area could be slim pickings. Something has to run the fan belt of the last petrol driven vehicle doesn't it ! Sorry about the digression, but back to us. Do folks consider the simplicity of what we have in the acne market ? A simple topical gel that is superior to what's out there and is novel and disruptive. Do not forget that our market could be a billion per annum and a ten per cent of that would not be too greedy. In fact, that has to be conservative but i would take ten percent anyday.

That is just one part of BOT. Yes it all takes time but we are not injecting anybody, we are not immunosuppressives, we are not toxic, we are safe.

Spring is in the air on day one.